Press Releases
August 01, 2003
Stratatech Corporation Wins $2M Grant from U.S. Dept. of Commerce
U.S. Representative Tammy Baldwin today announced that Stratatech Corporation of Madison will receive a federal grant $2 million to develop technology enabling the dry storage of living human tissues. This technology will allow Stratatech and a wide range of other companies to fully realize the remarkable potential of cell-based therapies and tissue engineering for the treatment of a variety of human diseases.
Presented by the Department of Commerce, the grant is part of the Advanced Technology Program (ATP), which assists with funding to develop technologies that promise significant commercial value and widespread benefits for the nation.
"Stratatech is thrilled to have this technology recognized for its importance by the U.S. Department of Commerce," said Dr. Lynn Allen-Hoffmann, President and CEO of Stratatech. "We are excited not only for what the technology could mean to us but also what it means for other companies in the field, doctors who use these products, and the patients who need them."
The ATP partners with companies of all sizes, universities and not-for-profits, encouraging them to take on greater technical challenges with potentially large benefits for the nation - challenges they could not or would not do alone.
Grants are selected through open, peer-reviewed competitions, and all industries and all fields of science and technology are eligible. The Stratatech award was one of only 16 ATP grants announced out of 136 proposals in the second round of 2003 ATP funding. In all, the ATP has awarded 63 grants, out of nearly 700 proposals in 2003.
Formed in 2000, Stratatech Corporation is developing a range of living skin tissue products for the treatment of burns and chronic wounds that plague diabetics and the elderly. In the past year, Congresswoman Baldwin has nominated Dr. Allen-Hoffmann for a number of accolades for her cutting-edge research. "I am so honored my district is home to high tech firms like Stratatech," Baldwin said. "After touring their facility and learning more about their research, I was confident in Stratatech's ability to revolutionize wound care as we know it."
